Sinovac Life Sciences Co., Ltd. clinical trials

A subsidiary of Sinovac Biotech Co., Ltd

The registry lists 26 studies whose lead sponsor is Sinovac Life Sciences Co., Ltd.. 11 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 22, 2026.

Studies

Recruiting first, then most recently updated. Showing 26 of 26. All Sinovac Biotech Co., Ltd studies →

• A Lot-to-Lot Consistency Clinical Trial of PCV13Not yet recruitingNCT07832500Phase 3

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• A Phase Ⅲ Clinical Study of SNA02-48 InjectionNot yet recruitingNCT07633119Phase 3

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)Not yet recruitingNCT07593924Phase 3

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Clinical Trial of PCV24 in Infants Aged 2-23 MonthsRecruitingNCT06800261Phase 1

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Clinical Trial of 13-Valent Pneumococcal Conjugate VaccineRecruitingNCT06617715Phase 3

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate VaccineNot yet recruitingNCT07374510Phase 1

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 YearsRecruitingNCT07300644Phase 2

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)RecruitingNCT06967272Phase 2

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 PatientsRecruitingNCT06042764Phase 2

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• SA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19RecruitingNCT06050460Phase 1

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health PeopleRecruitingNCT06048393Phase 1

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult ParticipantsCompletedNCT06939777Phase 1/2

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Clinical Trial of PCV24 in Adults Aged ≥18 YearsCompletedNCT07543198Phase 1/2

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)CompletedNCT06950645Phase 1

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Clinical Trial of PCV24 in Children Aged 2-17 YearsCompletedNCT06550830Phase 1

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate VaccineCompletedNCT05092386Phase 1

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Clinical Trial of PCV24 in AdultsCompletedNCT06474377Phase 1

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old PopulationCompletedNCT06049940Phase 3

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 VaccineActive, not recruitingNCT05329038Phase 4

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and AdolescentsCompletedNCT04992208Phase 4

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and AdolescentsCompletedNCT04884685Phase 2

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk PopulationsStatus unknownNCT05664919Not applicable

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 PeopleStatus unknownNCT05667714Not applicable

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)CompletedNCT04383574Phase 1/2

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the ElderlyCompletedNCT05398926Phase 4

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.

• Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19CompletedNCT05165966Phase 4

  Sponsor listed in the registry: Sinovac Life Sciences Co., Ltd.